Buch Construction company information, Employees & Contact Information

Consumer confidence dips as markets rally The Real Economy Blog

Recent Trends in the Pharmacological Treatment of Chronic Migraine: A Systematic Review of Randomized Controlled Trials Cureus

FM appoints Liberty Mutual’s Erbig as new CFO Insurance Insider US

Hagerty Reports Classic Car Market Cooling Motorious

Nobuhiro Hosoki Cinema Daily US

EY US - Home | Building a better working world EY

Driving change: The new roadmap for automotive retail transformation RSM

Anesthetic Μanagement of an Emergency Craniotomy in a Patient With Noonan Syndrome: A Case Report Cureus

‘No further re-underwriting of the casualty book’ needed: Everest CFO Insurance Insider US

Massive Nationwide Cancer Charity Fraud Scheme Serves as Warning Oncology News Central

AstraZeneca Foundation awards over $1.4M in third year grants to advance healthcare access; announces 2026 call for applications AstraZeneca US

Polymerase Chain Reaction-Confirmed Lyme Neuroborreliosis Masked by Pseudomonas Mastoiditis in a Mexican Traveler: A Case Report Cureus

Holly Starks Acquires the Flumberico Brand, Expanding the Vision Behind flumberico.us.com Yahoo Finance

Market Minute: Falling bond yields and economic imbalances The Real Economy Blog

The Hartford pulling back in large property over pricing concerns Insurance Insider US

AdvaMed Code of Ethics® AdvaMed® - Advanced Medical Technology Association®

Incidental Hibernoma With an Atypical Presentation: Diagnostic Approach, Pathologic Correlation, and Lessons Learned Cureus

Any move back to admitted market won’t offset E&S growth: Powell Brown Insurance Insider US

FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery AstraZeneca US

A Colloid Cyst Masquerading As Idiopathic Intracranial Hypertension in a Young Woman: A Diagnostic Pitfall Cureus

BofA Launches ‘Golf with Us’ to Bring Affordable Rounds to More Than 50,000 Youth Nationwide Bank of America

Car donation charity fined millions, accepts fundraising restrictions in Colorado and 18 other states CBS News

U.S.A. Home Hitachi Global

Empowering Action in Asthma Care This Season and Beyond AstraZeneca US

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial AstraZeneca US

iPR Pharmaceuticals Earns its 1st EPA’s ENERGY STAR® Certification for Superior Energy Efficiency AstraZeneca US

AstraZeneca impact in the US AstraZeneca US

Our impact, our people AstraZeneca US

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D AstraZeneca US

Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial AstraZeneca US

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025 AstraZeneca US

Celebrating National Nonprofit Day: Partnerships That Transform Healthcare Access AstraZeneca US

AIRSUPRA ® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol AstraZeneca US

Delaware AG joins lawsuit against 'deceptive' breast cancer fundraising operation The News Journal

TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer AstraZeneca US

CONSUMER PROTECTION NEWS: FTC, 19... VitalLaw.com

Update on CARES Phase III clinical program of anselamimab in light chain amyloidosis AstraZeneca US

Nationwide Fake Cancer Charity Scam Busted, Kars-R-Us.com Inc. Accused Hoodline

Gefurulimab dual-binding nanobody demonstrated statistically significant and clinically meaningful improvement in functional activities of daily living in adults with generalized myasthenia gravis in PREVAIL Phase III trial AstraZeneca US

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma AstraZeneca US

Partnerships in Motion: How Cross-Sector Collaboration is Powering Broader Clinical Trial Representation AstraZeneca US

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial AstraZeneca US

Trump calls for using US cities as a ‘training ground’ for military in unusual speech to generals Federal News Network

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial AstraZeneca US

Be careful with online Joann closure sales Canton Repository

AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer AstraZeneca US

Luv n' care Recalls Nuby Stroller Fans Due to Laceration Injury Hazard U.S. Consumer Product Safety Commission (.gov)

Alexion data presented at the 2025 AAN Annual Meeting highlight advancements in improving care for rare neurological diseases AstraZeneca US

American Rheinmetall secures order for T-158 tracks Rheinmetall

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial AstraZeneca US

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer AstraZeneca US

Announcing the 2024 Power of Us Award winners AstraZeneca US

Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca US

US Com Sec Lutnick says again on tariffs that 10 is baseline, no one’s going below 10 TradingView

IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer AstraZeneca US

TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial AstraZeneca US

Rheinmetall completes acquisition of Loc Performance in the USA Rheinmetall

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer AstraZeneca US

Announcing the 2024-2025 US ACT on Health Equity Community Investments Recipients AstraZeneca US

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca US

TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps AstraZeneca US

Collective Action to Advance Health Equity AstraZeneca US

TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer AstraZeneca US

AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites AstraZeneca US

FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis AstraZeneca US

What science can do AstraZeneca US

AIRSUPRA (PT027) approved in the US for asthma AstraZeneca US

Announcing the 2023 Power of Us Award winners AstraZeneca US

Scot Anderson Womble Bond Dickinson

Affordability AstraZeneca US

TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer AstraZeneca US

The Real Economy: October 2025 RSM

US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) AstraZeneca US

Tracy A. Bacigalupo Womble Bond Dickinson

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors AstraZeneca US

Leadership RSM

Investigator Sponsored Studies (ISS) Program Novo Nordisk U.S. Website

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in US for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens AstraZeneca US

TEZSPIRE approved for self-administration in the US with a new pre-filled pen AstraZeneca US

AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial AstraZeneca US

FluMist approved for self-administration in the US AstraZeneca US

IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial AstraZeneca US

Who We Are Otsuka US

WAINUA (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis AstraZeneca US

ispace-US and Rhea Space Activity Sign Payload Services Agreement Aimed at Expanding Deep Space Technological Capabilities ispace

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer AstraZeneca US

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH AstraZeneca US

Nonprofit and education RSM

TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer AstraZeneca US

IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery AstraZeneca US

ispace - U.S. Announces new U.S. Headquarters, Unveils APEX 1.0 Lunar Lander, Provides Updates on Mission 3 ispace

Careers AstraZeneca US

Alexander P. Wharton Womble Bond Dickinson

Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer AstraZeneca US

FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients AstraZeneca US

Product patents Novo Nordisk U.S. Website

ispace-U.S. Accelerates its Mission 3 Utilizing Agile Development with Fusion by Stoke Space ispace

Contact Us AstraZeneca US

CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma AstraZeneca US

IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer AstraZeneca US